About Vitality Biopharma (OTCMKTS:VBIO)
Vitality Biopharma, Inc., formerly Stevia First Corp., is engaged in the development of cannabinoid prodrug pharmaceuticals. The Company unlocks the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Its product pipeline includes cannabosides, VITA-100 and VITA-210. Cannabosides are cannabinoid glycoside prodrugs. VITA-100 is an oral cannabinoid formulation containing cannabosides that is being developed for treatment of inflammatory bowel disease, epilepsy, schizophrenia, and other disorders. VITA-210 is a cannabinoid glycoside prodrug being developed primarily for treatment of pain and muscle spasticity in multiple sclerosis and in rare white matter disorders. The Company's facilities include laboratories and a manufacturing suite for good manufacturing practices (GMPs) production, which will be used for pharmaceutical-grade production of products to be tested in clinical trials.
Industry, Sector and Symbol
Trailing P/E Ratio-5.96754943388923
Forward P/E RatioN/A
Sales & Book Value
Price / Sales257.51
Price / CashN/A
Book Value$0.02 per share
Price / Book90.00
Return on Equity-1,227.89%
Return on Assets-443.66%
Vitality Biopharma (OTCMKTS:VBIO) Frequently Asked Questions
What is Vitality Biopharma's stock symbol?
Vitality Biopharma trades on the OTCMKTS under the ticker symbol "VBIO."
Who are some of Vitality Biopharma's key competitors?
Some companies that are related to Vitality Biopharma include Novan (NOVN), Regulus Therapeutics (RGLS), Xenon Pharmaceuticals (XENE), Histogenics (HSGX), Novelion Therapeutics (NVLN), Alimera Sciences (ALIM), MEI Pharma (MEIP), Applied Genetic Technologies (AGTC), SCYNEXIS (SCYX), Vascular Biogenics (VBLT), Axsome Therapeutics (AXSM), Sophiris Bio (SPHS), Brainstorm Cell Therapeutics (BCLI), Opiant Pharmaceuticals (OPNT), Versartis (VSAR), Aptevo Therapeutics (APVO), Arcturus Therapeutics (ARCT) and Caladrius Biosciences (CLBS).
Who are Vitality Biopharma's key executives?
Vitality Biopharma's management team includes the folowing people:
- Avtar S. Dhillon M.D., Chairman of the Board (Age 56)
- Robert T. Brooke, Chief Executive Officer, Director (Age 36)
- Anthony E. Maida III, Ph.D., Independent Director (Age 65)
Has Vitality Biopharma been receiving favorable news coverage?
News coverage about VBIO stock has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vitality Biopharma earned a coverage optimism score of 0.21 on Accern's scale. They also gave news headlines about the company an impact score of 46.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Vitality Biopharma?
Shares of VBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vitality Biopharma's stock price today?
One share of VBIO stock can currently be purchased for approximately $1.80.
How big of a company is Vitality Biopharma?
Vitality Biopharma has a market capitalization of $43.03 million and generates $160,000.00 in revenue each year. The company earns $-5,210,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. Vitality Biopharma employs 7 workers across the globe.
How can I contact Vitality Biopharma?
Vitality Biopharma's mailing address is 1901 AVENUE OF THE STARS 2ND FLOOR, LOS ANGELES CA, 90067. The company can be reached via phone at 530-231-7800 or via email at [email protected]
MarketBeat Community Rating for Vitality Biopharma (VBIO)MarketBeat's community ratings are surveys of what our community members think about Vitality Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vitality Biopharma (OTCMKTS:VBIO) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Vitality Biopharma (OTCMKTS:VBIO) Earnings History and Estimates Chart
Vitality Biopharma (OTCMKTS VBIO) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2017||Q2 2018||($0.04)||$0.03 million||View||N/A|
|8/10/2017||Q1 2018||($0.05)||$0.03 million||View||N/A|
|6/28/2017||Q4 2017||($0.05)||$0.03 million||View||N/A|
|2/14/2017||Q3 2017||($0.06)||$0.04 million||View||N/A|
|11/17/2016||Q2 2017||($0.09)||$0.05 million||View||N/A|
|8/16/2016||Q1 2017||($0.04)||$0.05 million||View||N/A|
|6/24/2016||Q4 2016||($0.10)||$0.05 million||View||N/A|
Vitality Biopharma (OTCMKTS:VBIO) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Vitality Biopharma (OTCMKTS:VBIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Vitality Biopharma (OTCMKTS VBIO)
No insider trades for this company have been tracked by MarketBeat.com
Vitality Biopharma (OTCMKTS VBIO) News Headlines
Vitality Biopharma (OTCMKTS:VBIO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Vitality Biopharma (OTCMKTS:VBIO) Income Statement, Balance Sheet and Cash Flow Statement
Vitality Biopharma (OTCMKTS VBIO) Stock Chart for Wednesday, March, 21, 2018